2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes

被引：288
|
作者：
Das, Sandeep R. [1 ]
Everett, Brendan M. [2 ]
Birtcher, Kim K. [3 ]
Brown, Jenifer M. [4 ]
Januzzi, James L., Jr. [5 ]
Kalyani, Rita R. [6 ]
Kosiborod, Mikhail [7 ,8 ]
Magwire, Melissa [9 ]
Morris, Pamela B. [10 ,11 ]
Neumiller, Joshua J. [12 ,13 ]
Sperling, Laurence S. [14 ,15 ,16 ]
机构：
[1] UT Southwestern Med Ctr, Med, Dallas, TX 75390 USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Houston, Coll Pharm, Houston, TX 77004 USA
[4] Brigham & Womens Hosp, Cardiol, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Med, Boston, MA 02115 USA
[6] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD 21218 USA
[7] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[8] Univ Missouri Kansas City, Med, Kansas City, MO USA
[9] St Lukes Hlth Syst, Cardiometabol Ctr Alliance, Kansas City, MO USA
[10] Med Univ South Carolina, Seinsheimer Cardiovasc Hlth Program, Columbia, SC USA
[11] Med Univ South Carolina, Womens Heart Care, Columbia, SC USA
[12] Washington State Univ, Pullman, WA 99164 USA
[13] Washington State Univ, Pharmacotherapy, Pullman, WA 99164 USA
[14] Emory Heart Dis Prevent Ctr, Med Cardiol, Atlanta, GA USA
[15] Emory Univ, Atlanta, GA 30322 USA
[16] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Global Hlth, Atlanta, GA 30322 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 09期
关键词：
ACC Expert Consensus Decision Pathway; atherosclerotic cardiovascular disease; cardiovascular risk reduction; diabetes; GLP-1RA; SGLT2; inhibitor; type; 2; PEPTIDE-1 RECEPTOR AGONISTS; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; HEART-FAILURE; 2019; METHODOLOGY; GLUCOSE CONTROL; DOUBLE-BLIND; EMPAGLIFLOZIN; DISEASE; OUTCOMES;
D O I：
10.1016/j.jacc.2020.05.037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1117 / 1145
页数：29
相关论文
共 50 条
  • [41] Clinical cardiovascular phenotypes and the pattern of future events in patients with type 2 diabetes
    Malik, Mariam Elmegaard
    Andersson, Charlotte
    Blanche, Paul
    D'Souza, Maria
    Madelaire, Christian
    Zareini, Bochra
    Lamberts, Morten
    Kristensen, Soren Lund
    Sattar, Naveed
    McMurray, John
    Kober, Lars
    Torp-Pedersen, Christian
    Gislason, Gunnar
    Schou, Morten
    CLINICAL RESEARCH IN CARDIOLOGY, 2023, 112 (02) : 215 - 226
  • [42] Type 2 diabetes, thiazolidinediones, and cardiovascular risk
    Taylor, Clare
    Hobbs, F. D. Richard
    BRITISH JOURNAL OF GENERAL PRACTICE, 2009, 59 (564) : 520 - 524
  • [43] Adiponectin, type 2 diabetes and cardiovascular risk
    Lindberg, Soren
    Jensen, Jan Skov
    Bjerre, Mette
    Pedersen, Sune H.
    Frystyk, Jan
    Flyvbjerg, Allan
    Galatius, Soren
    Jeppesen, Jorgen
    Mogelvang, Rasmus
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2015, 22 (03) : 276 - 283
  • [44] Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
    Marx, Nikolaus
    McGuire, Darren K.
    EUROPEAN HEART JOURNAL, 2016, 37 (42) : 3192 - +
  • [45] Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?
    Deed, Gary
    Atherton, John J.
    d'Emden, Michael
    Rasalam, Roy
    Sharma, Anita
    Sindone, Andrew
    DIABETES THERAPY, 2019, 10 (05) : 1625 - 1643
  • [46] Should Metformin Remain First-Line Medical Therapy for Patients with Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease? An Alternative Approach
    Harrington, Josephine L.
    Rocha, Natalia de Albuquerque
    Patel, Kershaw V.
    Verma, Subodh
    McGuire, Darren K.
    CURRENT DIABETES REPORTS, 2018, 18 (09)
  • [47] Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
    Eliasson, Bjorn
    Ekelund, Jan
    Amberntsson, Rikard
    Miftaraj, Mervete
    Svensson, Ann-Marie
    DIABETES THERAPY, 2019, 10 (04) : 1523 - 1530
  • [48] Plasma Trimethylamine N-Oxide and Risk of Cardiovascular Events in Patients With Type 2 Diabetes
    Croyal, Mikael
    Saulnier, Pierre-Jean
    Aguesse, Audrey
    Gand, Elise
    Ragot, Stephanie
    Roussel, Ronan
    Halimi, Jean-Michel
    Ducrocq, Gregory
    Cariou, Bertrand
    Montaigne, David
    Wargny, Matthieu
    Krempf, Michel
    Hadjadj, Samy
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (07) : 2371 - 2380
  • [49] Type 2 diabetes and cardiovascular disease: risk reduction and early intervention
    Hinnen, Debbie
    Kruger, Davida
    Magwire, Melissa
    POSTGRADUATE MEDICINE, 2023, 135 (01) : 2 - 12
  • [50] Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
    Tanaka, Atsushi
    Shimabukuro, Michio
    Teragawa, Hiroki
    Okada, Yosuke
    Takamura, Toshinari
    Taguchi, Isao
    Toyoda, Shigeru
    Tomiyama, Hirofumi
    Ueda, Shinichiro
    Higashi, Yukihito
    Node, Koichi
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
12345